Loading market dashboard
Spyre Therapeutics, Inc.
SYREHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 51,300 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on June 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
Enrollment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of the SKYWAY basket trial are complete
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:
WALTHAM, Mass. , May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare Conference - New YorkDate: Wednesday, June 3, 2026Fireside Time: 12:15 pm ET Event: Goldman Sachs 47th Annual Global Healthcare Conference - MiamiDate: Monday, June 8, 2026Fireside Time: 10:00 am ET Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the rheumatoid arthritis (“RA”) sub-study of the Phase 2 SKYWAY basket trial Remain on track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further strengthened the balance sheet with $463 million gross proceeds from an underwritten public offering of common stock $1.2 billion in pro forma cash, cash equivalents, and marketable securities as of March 31, 2026 , with expected runway into the second half of 2029 WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases (“RD”), today announced its first quarter 2026 financial results and provided program and corporate updates.
WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 20,800 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on May 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 975,000 additional shares, at a public offering price per share of $62.00.
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s share price gapped up before the market opened on Tuesday after Robert W. Baird raised their price target on the stock from $65.00 to $90.00. The stock had previously closed at $63.27, but opened at $67.68. Robert W. Baird currently has an outperform rating on the stock.
WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $62.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $403.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $60.5 million of shares of the Company's common stock at the public offering price, less the underwriting discount.
Spyre Therapeutics delivered strong Phase 2 data for SPY001, showing rapid, deep efficacy and a clean safety profile in ulcerative colitis. SPY001 achieved a 9.2-point RHI reduction, 40% clinical remission, and 51% endoscopic improvement at 12 weeks, suggesting best-in-class potential. Valuation reflects high expectations for SPY001 and combination regimens, with a $3-4B enterprise value and significant premium for future innovation.
WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional $45.0 million of shares of common stock at the public offering price, less the underwriting discount. All of the shares of common stock in the offering will be sold by Spyre.
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
• Spyre Therapeutics stock is approaching key resistance levels. Why is SYRE stock breaking out?
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results.
The CEO of Spyre Therapeutics reported selling 15,000 shares for a total transaction value of about $740,000 on April 1, 2026. The transaction represented 2.33% of Cameron Turtle's directly held common stock holdings and reduced direct ownership to 627,540 common shares post-sale, as reported in the Form 4.
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $49.33, for a total value of $739,950.00. Following the sale, the chief executive officer directly owned 627,540 shares in the company,
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) CFO Scott Burrows sold 7,500 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $49.34, for a total transaction of $370,050.00. Following the transaction, the chief financial officer owned 97,994 shares of the company's stock, valued
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 70,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on April 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both trading activity and share price appreciation.
Spyre Therapeutics, Inc. receives a Strong Buy rating, driven by positive phase 1 data and robust pipeline progress in IBD and rheumatic diseases. SPY001 demonstrated a half-life 4x greater than ENTYVIO, supporting quarterly or twice-yearly dosing for ulcerative colitis in the ongoing phase 2 SKYLINE trial. Accelerated recruitment in the phase 2 SKYWAY RA sub-study brings the anti-TL1A SPY072 data readout forward to Q3 2026, enhancing SYRE's near-term catalysts.
B Group Inc. increased its holdings in Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 25.0% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 100,000 shares of the company's stock after buying an additional 20,000 shares during the period. Spyre Therapeutics comprises approximately 1.3% of B
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript
